Immunome, Inc.

Immunome, Inc.

IMNM·NASDAQ

$19.78

-0.15%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.89B
EPS-2.4300
P/E Ratio-8.14
Earnings Date08/05/2026

imnm

Sales/Maturities of Investments

Last Annual Value

200.00M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Immunome, Inc.

Immunome, Inc. Competitors Analysis of Sales/Maturities of Investments

IMNM · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
200.00M
N/AN/AN/A 
200.89M
N/AN/AN/A
1.05B
5.6%16.6%N/A
231.63M
71.0%N/AN/A
17.50M
N/AN/AN/A
596.29M
23.0%27.8%9.4%
506.16M
39.7%N/AN/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
570.00M
20.3%N/AN/A
371.74M
110.4%27.3%46.0%
Immunome, Inc.

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.78, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

Intrinsic Value
Current Price: $19.78